156722-18-8
156722-18-8 structure
- Name: Rostafuroxin
- Chemical Name: (3β,5β,14β,17α)-17-(3-Furyl)androstane-3,14,17-triol
- CAS Number: 156722-18-8
- Molecular Formula: C23H34O4
- Molecular Weight: 374.514
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Na+/K+ ATPase
- Create Date: 2018-05-28 08:00:00
- Modify Date: 2024-01-02 17:50:39
-
Rostafuroxin(PST 2238) is a antihypertensive compound; Na,K-ATPase antognist;displaced [3H]ouabain from the dogkidney Na+,K+-ATPase with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: Na+,K+-ATPase modulator; ouabain antagonistin vitro: PST 2238 displaced [3H]ouabain from the dog kidney Na+,K+-ATPase receptor (IC50 ) 1.5X 10-6M), was devoid of cardiac inotropic activity in isolated guinea pig atria, and showed no affinity up to 10-4 M with general (R1, R2, a1, a2, A1, A2, M1, M2, H1, H2, 5-HT1, 5-HT2, Ca2+ channels, TXA2/PGH2, PAF, GABAA, GABAB, DA-NE-5-HT uptake, glutammate,glycine, benzodiazepine) and hormonal (estrogenic, progestinic, androgenic, mineralcorticoid) receptors [1]. At molecular level, in the kidney, Rostafuroxin antagonizes EO triggering of the Src-epidermal growth factor receptor (EGFr)-dependent signaling pathway leading to renal Na+-K+ pump, and ERK tyrosine phosphorylation and activation [3].in vivo: PST 2238, given orally at very low doses (1 and 10 microg/kg for 5-6 weeks), reduced the development of hypertension in MHS rats and normalized the increased renal Na,K-ATPase activity and mRNA levels, whereas it did not affect either blood pressure or Na,K-ATPase in Milan-normotensive (MNS) rats [2].
| Name | (3β,5β,14β,17α)-17-(3-Furyl)androstane-3,14,17-triol |
|---|---|
| Synonyms |
UNII-P848LCX62B
Rostafuroxin 24-Norchola-20,22-diene-3,14,17-triol, 21,23-epoxy-, (3β,5β,14β)- (3β,5β,14β,17α)-17-(3-Furyl)androstane-3,14,17-triol Androstane-3,14,17-triol, 17-(3-furanyl)-, (3β,5β,14β,17α)- PST2238 |
| Description | Rostafuroxin(PST 2238) is a antihypertensive compound; Na,K-ATPase antognist;displaced [3H]ouabain from the dogkidney Na+,K+-ATPase with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: Na+,K+-ATPase modulator; ouabain antagonistin vitro: PST 2238 displaced [3H]ouabain from the dog kidney Na+,K+-ATPase receptor (IC50 ) 1.5X 10-6M), was devoid of cardiac inotropic activity in isolated guinea pig atria, and showed no affinity up to 10-4 M with general (R1, R2, a1, a2, A1, A2, M1, M2, H1, H2, 5-HT1, 5-HT2, Ca2+ channels, TXA2/PGH2, PAF, GABAA, GABAB, DA-NE-5-HT uptake, glutammate,glycine, benzodiazepine) and hormonal (estrogenic, progestinic, androgenic, mineralcorticoid) receptors [1]. At molecular level, in the kidney, Rostafuroxin antagonizes EO triggering of the Src-epidermal growth factor receptor (EGFr)-dependent signaling pathway leading to renal Na+-K+ pump, and ERK tyrosine phosphorylation and activation [3].in vivo: PST 2238, given orally at very low doses (1 and 10 microg/kg for 5-6 weeks), reduced the development of hypertension in MHS rats and normalized the increased renal Na,K-ATPase activity and mRNA levels, whereas it did not affect either blood pressure or Na,K-ATPase in Milan-normotensive (MNS) rats [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 451.3±45.0 °C at 760 mmHg |
| Molecular Formula | C23H34O4 |
| Molecular Weight | 374.514 |
| Flash Point | 226.7±28.7 °C |
| Exact Mass | 374.245697 |
| PSA | 73.83000 |
| LogP | 3.56 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.591 |
| Storage condition | 2-8℃ |
| RIDADR | NONH for all modes of transport |
|---|